{"id":725,"date":"2004-11-01T12:03:00","date_gmt":"2004-11-01T11:03:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/neues-ueber-venenthrombosen-bei-patientinnen-der-whi-studie"},"modified":"2004-11-01T12:03:00","modified_gmt":"2004-11-01T11:03:00","slug":"neues-ueber-venenthrombosen-bei-patientinnen-der-whi-studie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2004\/neues-ueber-venenthrombosen-bei-patientinnen-der-whi-studie","title":{"rendered":"Neues \u00fcber Venenthrombosen bei Patientinnen der WHI-Studie"},"content":{"rendered":"<p>In der von uns fr\u00fcher besprochenen Women\u2019s-Health-Initiative-Studie (WHI), die nach etwa 5,5 Jahren Laufzeit wegen eines signifikant erh\u00f6hten Brustkrebsrisikos bei Einnahme konjugierter \u00d6strogene aus Stutenharn (Conjugated equine estrogens = CEE) plus 2,5 mg Medroxyprogesteronacetat (MPA) pro Tag beendet wurde, war auch das Risiko, ein kardiovaskul\u00e4res Ereignis zu erleiden, unter Hormontherapie im Vergleich mit Plazebo erh\u00f6ht [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In der von uns fr\u00fcher besprochenen Women\u2019s-Health-Initiative-Studie (WHI), die nach etwa 5,5 Jahren Laufzeit wegen eines signifikant erh\u00f6hten Brustkrebsrisikos bei Einnahme konjugierter \u00d6strogene aus Stutenharn (Conjugated equine estrogens = CEE) plus 2,5 mg Medroxyprogesteronacetat (MPA) pro Tag beendet wurde, war auch das Risiko, ein kardiovaskul\u00e4res Ereignis zu erleiden, unter Hormontherapie im Vergleich mit Plazebo erh\u00f6ht [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[61,57,358,363,360,364,357,362,66,359,54,51,55,1088],"class_list":["post-725","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-beinvenenthrombose","tag-estrogene-gestagene","tag-het","tag-hormonersatz-therapie","tag-hormonersatztherapie","tag-hrt","tag-klimakterium","tag-menopause","tag-oestrogene-gestagene","tag-postmenopause","tag-thromboembolie","tag-thrombose","tag-venenthrombose","tag-whi-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/725","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=725"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/725\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=725"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=725"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=725"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}